Search clinical trials for: Placebo to sitagliptin plus metformin

Total 2609 results

Duke University

Completed

Steps to Health: Targeting Obesity in the Health Care Workplace

Overweight | Obese

United States
Andalusian School of Public Health

Completed

Effectiveness of Two Interventions in Patients With Low Educational Level With Diabetes to Reduce Inequalities in Self-care Behavior

Diabetes Mellitus Type 2

Spain
Khyber Medical University Peshawar

Completed

Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome (PCOS)

PCOS

Pakistan
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

Type 2 Diabetes Mellitus
Zagazig University

Completed

L-carnitine and Metformin in Obese PCOS Women.

PCOS

Egypt
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
University of Kansas Medical Center
National Institute of Nursing Research (NINR)

Completed

Teen and Young Adult Connections for Support From Multidisciplinary Professionals & Peers

Malnutrition | Malabsorption | Short Bowel Syndrome

United States
Merck Sharp & Dohme LLC

Completed

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Type 2 Diabetes Mellitus
Anji Pharma

Suspended

Investigational Study of Delayed Release Metformin (DREAM-T2D)

Diabetes Mellitus, Type 2

Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
Novartis Pharmaceuticals

Completed

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Latvia, Peru, Lithuania, Israel, Norway, Finland, Argentina, Austria, Belgium, Germany, Greece, Guatemala, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, Venezuela
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Type 2 Diabetes

Germany
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
Eli Lilly and Company
Berry Consultants; United BioSource, LLC; Tessella Inc.

Completed

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Diabetes Mellitus, Type 2

United States, Korea, Republic of, Russian Federation, Puerto Rico, Romania, Spain, Taiwan, Mexico, France, Germany, India, Canada, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada, France, Spain, Israel, Australia, Austria
Boehringer Ingelheim
Eli Lilly and Company

Completed

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Diabetes Mellitus, Type 2

China, Malaysia, Philippines, Vietnam
University Health Network, Toronto

Withdrawn

LIpitor and biGuanide to Androgen Delay Trial (LIGAND)

Prostate Cancer

Canada
University of Diyala

Completed

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

Type 2 Diabetes

Iraq
Norwegian University of Science and Technology

Completed

Treatment of Latent Autoimmune Diabetes of the Adult (LADA)

Diabetes

Norway
GlaxoSmithKline

Completed

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States
AstraZeneca

Withdrawn

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Type 2 Diabetes

Brazil
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Healthy

Germany
Galenicum Health

Completed

Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers

Type 2 Diabetes | Bioequivalence

Canada
Galenicum Health

Completed

Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers

Diabetes Mellitus, Type 2 | Bioequivalence

Canada
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

Type 2 Diabetes Mellitus
Verona Pharma plc
Iqvia Pty Ltd; LGC Limited

Completed

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

COPD

United States
Sun Yat-sen University

Completed

Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects (LIGHT-ON)

Non-alcoholic Fatty Liver Disease

China
AstraZeneca

Completed

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation, Romania, Poland, Czech Republic, Puerto Rico, Hungary
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Healthy

Germany
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Healthy
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
AstraZeneca

Completed

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Type 2 Diabetes

United States
Gilead Sciences

Completed

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Type 2 Diabetes Mellitus

United States, Russian Federation, Israel, South Africa, India, Hungary, Ukraine, Canada, Czech Republic, Mexico, Poland
Colorado State University
National Center for Complementary and Integrative Health (NCCIH)

Terminated

The Moving 2 Mindful (M2M) Study: Mindfulness Group + Ecological Momentary Intervention (M2M)

Stress | Anxiety

United States
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Type 2 Diabetes Mellitus

United States, Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, South Africa, Argentina, Canada, Germany, Hungary, Israel, Romania, Slovakia, India, Belgium, France, Puerto Rico
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Type 2 Diabetes Mellitus
Cairo University

Completed

Effect of Aerobic Exercise on Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

Egypt
Fundación para la Investigación del Hospital Clínico...

Recruiting

Effects of a Supervised Training Program on Functional Capacity in Patients With HFpEF and Chronotropic Incompetence (Training-HR)

Heart Failure With Preserved Ejection Fraction | Chronotropic Incompetence

Spain
Chang Gung Memorial Hospital
National Taiwan University Hospital; Chiayi Christian Hospital; Tainan Sin-lau...

Recruiting

Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

Stroke | Diabetes Mellitus

Taiwan
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Unknown

Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM

Type 2 Diabetes
AstraZeneca

Completed

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of, Mexico, South Africa, United States, Canada, Puerto Rico, Poland, Romania
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (PRELLIM)

Insulin Resistance | Prediabetic State

Mexico
Bristol-Myers Squibb

Completed

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

South Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico

3

Subscribe